

Sarah B Berman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4835675/publications.pdf>

Version: 2024-02-01

56
papers

3,667
citations

201674

27
h-index

189892

50
g-index

59
all docs

59
docs citations

59
times ranked

5498
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria. <i>Journal of Neurochemistry</i> , 1999, 73, 1127-1137.	3.9	582
2	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	10.2	383
3	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	30.7	351
4	Bcl-xL increases mitochondrial fission, fusion, and biomass in neurons. <i>Journal of Cell Biology</i> , 2009, 184, 707-719.	5.2	203
5	Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization. <i>Human Molecular Genetics</i> , 2011, 20, 927-940.	2.9	200
6	Modification of Dopamine Transporter Function: Effect of Reactive Oxygen Species and Dopamine. <i>Journal of Neurochemistry</i> , 1996, 67, 593-600.	3.9	152
7	Mitochondrial fission and fusion dynamics: the long and short of it. <i>Cell Death and Differentiation</i> , 2008, 15, 1147-1152.	11.2	130
8	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	7.6	122
9	Mitochondrial dynamics in Parkinson's disease. <i>Experimental Neurology</i> , 2009, 218, 247-256.	4.1	112
10	The interplay of neuronal mitochondrial dynamics and bioenergetics: Implications for Parkinson's disease. <i>Neurobiology of Disease</i> , 2013, 51, 43-55.	4.4	112
11	Quantitative Biochemical and Ultrastructural Comparison of Mitochondrial Permeability Transition in Isolated Brain and Liver Mitochondria: Evidence for Reduced Sensitivity of Brain Mitochondria. <i>Experimental Neurology</i> , 2000, 164, 415-425.	4.1	107
12	Glutamate excitotoxicity in neurons triggers mitochondrial and endoplasmic reticulum accumulation of Parkin, and, in the presence of N-acetyl cysteine, mitophagy. <i>Neurobiology of Disease</i> , 2015, 74, 180-193.	4.4	94
13	Inhibition of Glutamate Transport in Synaptosomes by Dopamine Oxidation and Reactive Oxygen Species. <i>Journal of Neurochemistry</i> , 1997, 69, 1185-1195.	3.9	93
14	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
15	Integrating multiple aspects of mitochondrial dynamics in neurons: Age-related differences and dynamic changes in a chronic rotenone model. <i>Neurobiology of Disease</i> , 2011, 41, 189-200.	4.4	79
16	DJ-1 knock-down impairs astrocyte mitochondrial function. <i>Neuroscience</i> , 2011, 196, 251-264.	2.3	77
17	Mitochondrial factors with dual roles in death and survival. <i>Oncogene</i> , 2006, 25, 4697-4705.	5.9	68
18	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	7.6	66

#	ARTICLE	IF	CITATIONS
19	Mild Cognitive Impairment that Does Not Progress to Dementia: A Population-Based Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 232-238.	2.6	52
20	Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress. <i>Journal of Neuroscience</i> , 2018, 38, 7505-7515.	3.6	51
21	Live imaging of mitochondrial dynamics in CNS dopaminergic neurons in vivo demonstrates early reversal of mitochondrial transport following MPP+ exposure. <i>Neurobiology of Disease</i> , 2016, 95, 238-249.	4.4	44
22	Outcomes of Interventional-MRI Versus Microelectrode Recording-Guided Subthalamic Deep Brain Stimulation. <i>Frontiers in Neurology</i> , 2018, 9, 241.	2.4	43
23	More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2015, 36, 2443.e21-2443.e26.	3.1	39
24	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	7.6	36
25	Variant-dependent heterogeneity in amyloid β^2 burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	10.2	34
26	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	4.4	31
27	Investigation of an amyloid precursor protein protective mutation (A673T) in a North American case-control sample of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1779.e15-1779.e16.	3.1	28
28	Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone. <i>Neurobiology of Disease</i> , 2016, 91, 247-261.	4.4	28
29	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	3.1	27
30	Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. <i>Psychiatry Research</i> , 1992, 42, 81-92.	3.3	25
31	The relevance of age and disease duration for intervention with subthalamic nucleus deep brain stimulation surgery in Parkinson disease. <i>Journal of Neurosurgery</i> , 2011, 114, 927-931.	1.6	24
32	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 69.	6.2	22
33	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	7.6	20
34	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	1.7	18
35	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	2.7	17
36	Hippocampal sclerosis, TDP β 43, and the duration of the symptoms of dementia of AD patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1546-1556.	3.7	15

#	ARTICLE	IF	CITATIONS
37	Ambient fine particulate matter exposure and incident mild cognitive impairment and dementia. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2185-2194.	2.6	14
38	Potential Role of Mic60/Mitofilin in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 898.	2.8	13
39	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.8	13
40	Update on huntington's disease. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 281-286.	4.2	7
41	PD and DLB: Brain imaging in Parkinson's disease and dementia with Lewy bodies. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 167-185.	1.7	7
42	Cognitive Functions Predict Trajectories of Sleepiness Over 10 Years: A Population-Based Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 520-527.	3.6	7
43	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. <i>Neurobiology of Disease</i> , 2022, 168, 105714.	4.4	7
44	Exploring the life cycle of mitochondria in neuropsychiatric diseases: Mitochondrial dynamics and quality control. <i>Neurobiology of Disease</i> , 2013, 51, 1-2.	4.4	5
45	Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. <i>Alzheimer's and Dementia</i> , 2020, 16, e041129.	0.8	4
46	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.8	4
47	Primary Embryonic Rat Cortical Neuronal Culture and Chronic Rotenone Treatment in Microfluidic Culture Devices. <i>Bio-protocol</i> , 2019, 9, .	0.4	3
48	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028.	0.8	3
49	Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049.	0.8	2
50	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
51	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2
52	Mitochondrial Fission-Fusion and Parkinson's Disease: A Dynamic Question of Compensatory Networks. , 2011, , 197-213.		1
53	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
54	P3-214: DEMENTIA WITH LEWY BODIES CONSORTIUM: METHODOLOGY AND INITIAL SUBJECT CHARACTERISTICS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1152.	0.8	0

#	ARTICLE	IF	CITATIONS
55	The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e042846.	0.8	0
56	Clinical Progression of Baseline Risk States for Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-8.	2.6	0